KRAS and non-small cell lung carcinoma: For non-metastatic locally advanced NSCLC patients with KRAS mutations, the median PFS and median OS of Trametinib (1.5mg) combined with concurrent radiotherapy and chemotherapy were 11 months and 38 months, respectively, with controllable safety.